

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/564,520	01/13/2006	Keizo Sugasawa	03327.2338	3500
22852 7590 05/16/2007 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP			EXAMINER	
			BARKER, MICHAEL P	
901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			ART UNIT	PAPER NUMBER
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	.,		1626	
			<u></u>	-
•			· MAIL DATE	DELIVERY MODE
			05/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/564,520	SUGASAWA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Michael P. Barker	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	l. ely filed the mailing date of this communication. C (35 U.S.C. § 133).				
Status						
 Responsive to communication(s) filed on 1/13/6 This action is FINAL. 2b) This Since this application is in condition for allowant closed in accordance with the practice under E 	action is non-final. nce except for formal matters, pro	·				
Disposition of Claims						
4) ⊠ Claim(s) 1-15 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-5 and 7-10 is/are rejected. 7) ⊠ Claim(s) 1 and 3-15 is/are objected to. 8) □ Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the examiner Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examiner	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119		•				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 4/19/06.	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal P 6) Other:	ate				

Art Unit: 1626

DETAILED ACTION

Claims 1-15 are pending in this Application. Claims 1-5 and 7-10 are rejected, and Claims 1 and 3-15 are objected to.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on April 19, 2006 was correctly filed. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS was considered by the Examiner. Please refer to Applicant's copy of PTO-1449, submitted herewith.

Claim Rejections - 35 USC § 102(b)

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2, 4, and 5 are rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent No. 5,380,736, issued January 10, 1995. The '736 patent discloses a species at col. 30, Table 8, Example No. 34, which anticipates Applicant's Markush language of Claim 1, wherein:

- o A is a lower alkylene (methylene in this case);
- o R^1 is represented by formula (II), R^{11} and R^{12} are lower alkyl;
- o R^2 is phenyl; and
- o R³ is an aromatic heterocycle (indolyl in this case).

Art Unit: 1626

Please note Claim 3 is not included in this rejection, because it includes the limitation, "wherein R^2 is thienyl or phenyl, each of which is substituted. ...". The '736 patent does not meet the limitation in which R^2 is phenyl and substituted. Claim 6 and its dependent claims are also not rejected here. Claim 6 includes a proviso in the definition of R^6 which overcomes the prior art, or carves around the prior art.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 2-5 recite the limitation, "The pharmaceutical composition". There is insufficient antecedent basis for this limitation in the claims, since Claim 1 is drawn to "A platelet increasing agent". Thus, to overcome this rejection, Applicant may consider rephrasing the preamble of Claim 1 to recite, "A pharmaceutical composition comprising..."

Likewise, Claims 7-10 recite the limitation, "The compound..." There is insufficient antecedent basis for this limitation in the claims, since Claim 6 is drawn to "A 2-acylaminothiazole derivative". Thus, to overcome this rejection, Applicant may consider rephrasing the preamble of Claim 6 to recite, "A compound".

Objections

Claims 1 and 6 are objected to for containing multiple periods within each claim. Claims are required to be in the form of one sentence only. Claims 1 and 6 each contain more than one sentence and more than one period.

Art Unit: 1626

Claims 3 and 6-15 are objected to for being based (or ultimately based) upon a rejected base claim.

Claims 4, 5, and 12 are objected to under 37 CFR 1.75(c) as being in improper multiple dependent form because of the language, "according to any of claims x to y...". See MPEP § 608.01(n). One suggestion to overcome this objection is to rewrite the disputed language as, "according to any one of claims x to y...".

Allowable Subject Matter

Aside from the outstanding rejections and objections, Claims 3 and 6-15 are drawn to allowable subject matter, and there are no prior art rejections to be made on these claims.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael P. Barker whose telephone number is (571) 272-4341. The examiner can normally be reached on Monday-Friday 8:00 AM- 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699. The unofficial fax phone for this group are (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

Application/Control Number: 10/564,520

Art Unit: 1626

applications is viable through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael P. Barker

Patent Examiner, AU 1626 Technology Center 1600 REBECCA ANDERSON

(for) Joseph McKane

Supervisory Patent Examiner, AU 1626

Page 5

Technology Center 1600